Entitlement Offer to raise $11m for Phase 3 clinical trial
Filed with ASX · · 4 pages · English
Avecho Biotechnology Limited on 6ix
In the deck
Earlier from Avecho Biotechnology
- Clinical CBD program expands with the Lambert Initiative
- December 2022 Quarterly Activities Report & Appendix 4C
- Athenex submits Avechos phytonadione to FDA pre-IND
- Avecho receives ethics approval for Phase III CBD trial
- AVE signs development agreement with Perrigo
Later from Avecho Biotechnology
- Prospectus
- Investor Presentation
- March 2023 Quarterly Activities Report & Appendix 4C
- Results of Entitlement Offer
- AVE commences manufacturing for Phase III trial
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology